Taking up reading, puzzles, and games even in one's 80s may provide cognitive protection
CMS says a final decision on coverage is not likely until next spring
Request follows reports that Biogen and the FDA held off-the-books meetings before the drug's approval that may have violated FDA protocol
Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use
FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial